LKFT

Healthcare Biotechnology

Lakefront Biotherapeutics NV

$29.32

-0.71 -2.36% today

Price History

Not enough data

Key Stats

Market Cap

1.92B

Avg Volume

261,504

P/E (TTM)

2.79

EPS

$10.52

52W High

$36.24

52W Low

$25.68

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-24.66

P/B Ratio

10.41

P/S Ratio

1.94

EV/EBITDA

63.75

EV/Revenue

36.61

Margins

Gross Margin 67.6%

Operating Margin (359.3%)

Net Margin 60.2%

EBITDA Margin 57.4%

Growth & Returns

Revenue Growth (YoY)

(81.5%)

Return on Equity

20.1%

Return on Assets

9.9%

Liquidity & Leverage

Current Ratio

32.84

Quick Ratio

32.65

Debt / Equity

0.00

Total Cash

2.24B

Total Debt

6.36M

About

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

lakefrontbio.com